Aldeyra Therapeutics, Inc. received a Complete Response Letter from the FDA on March 17, 2026, which indicates their drug reproxalap for dry eye disease did not demonstrate sufficient efficacy in studies. The company has enough funds to maintain operations until 2028, but must address FDA concerns before resubmitting their New Drug Application.